Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.45 |
| ▸ | GAPDH | P04406 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11061066 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL26801670 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL2493931 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL5707687 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL14274463 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL11726595 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL3496162 | 1.00 | USP2 (0.55) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL3272584 | 0.99 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL6022376 | 0.99 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 | |
| SCHEMBL3663518 | 0.99 | USP2 (0.54) | USP2POLBMEN1KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250319113-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| CN-119912510-A | Modulators of extracellular 5' -nucleotidases and uses thereof | 艾库斯生物科学有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-114395005-B | Modulators of extracellular 5' -nucleotidases and uses thereof | 艾库斯生物科学有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-12168023-B2 | Inhibitors of adenosine 5′-nucleotidase | ARCUS BIOSCIENCES, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240352057-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240285665-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-4600771-A | Process for the preparation of acylated sugars with a glycosidically bonded isothiocyanate group | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0142094-A2 | Method for the preparation of acylated sugars containing an isothiocyanate radical linked to position 1 of the glycose | BAYER AG (DE) | 1985-05-22 | — | — | EP | disclosed |
| EP-0072977-A1 | Process for the production of 2-beta-D-ribofuranosylthiazole-4-carboxamide | Starks Associates, Incorporated (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0065324-A1 | 1,3-Diazepine compounds | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1982-11-24 | — | — | EP | disclosed |
| EP-0034424-A2 | Seven-membered ring compounds as inhibitors of cytidine deaminase | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1981-08-26 | — | — | EP | disclosed |
| WO-1981002164-A1 | SEVEN-MEMBERED RING COMPOUNDS AS INHIBITORS OF CYTIDINE DEAMINASE | US COMMERCE (US) | 1981-08-06 | — | — | WO | disclosed |
| US-4282349-A | Crystalline ribofuranosyl halides and other derivatives and methods for producing same | BOARD OF CONTROL OF MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 1981-08-04 | — | — | US | disclosed |
| US-4275057-A | CANCER AND ANTITUMOR DRUG RESEARCH | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1981-06-23 | — | — | US | disclosed |
| US-4140850-A | IMMUNOSUPPRESSIVE, VIRICIDES, SILYLATION, CYCLIZATION, DESILYLATION | THE UPJOHN COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
| US-RE29835-E | PHARMACEUTICAL | ICN PHARMACEUTICALS (US) | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352057-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | USP2 2822/4885POLB 388/4885MEN1 2537/4885 |
| US-20250319113-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | USP2 2930/4885POLB 294/4885MEN1 2351/4885 |
| US-12168023-B2 | Inhibitors of adenosine 5′-nucleotidase | ENTPD5, NT5C2, ENTPD1 | USP2 2896/4885POLB 289/4885MEN1 2410/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | USP2 639/4885POLB 149/4885MEN1 4544/4885 |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | USP2 2850/4885POLB 356/4885MEN1 2547/4885 |
| US-20240285665-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | USP2 2930/4885POLB 294/4885MEN1 2351/4885 |
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | NTPCR, NT5C2, NT5E | USP2 2996/4885POLB 841/4885MEN1 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.